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Abstract Resveratrol, a natural phytoalexin found in grapes, is
well known for its presumed role in the prevention of heart
disease, associated with red wine consumption. We show here
that it is a remarkable inhibitor of ribonucleotide reductase and
DNA synthesis in mammalian cells, which might have further
applications as an antiproliferative or a cancer chemopreventive
agent in humans.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
Resveratrol (3,5,4P-trihydroxystilbene) is a natural phyto-
alexin found in grapes (Scheme 1). Its physiological function
is not well de¢ned but is thought to reside in the protection of
the plant from environmental stress and pathogenic attack [1].
On the other hand, it has been suggested to play a role in the
prevention of heart disease, associated with red wine con-
sumption, as it inhibits platelet aggregation, alters eicosanoid
synthesis and modulates lipid and lipoprotein metabolism [1].
Resveratrol was also recently shown to inhibit cellular events
associated with tumor initiation, promotion and progression
[2]. In the light of its very weak toxicity, at least in mouse
tumor models [2], it was suggested that resveratrol should be
investigated as a cancer chemopreventive agent in humans.
Still very little is known about the molecular basis for its
biological activities. As a polyphenol molecule, it is a radical
scavenger and has been shown to inhibit cyclooxygenase ac-
tivity [2]. Now we report that it is a remarkable inhibitor of
ribonucleotide reductase, the enzyme which provides prolifer-
ating cells with deoxyribonucleotides required for DNA syn-
thesis, during the early S-phase of the cell cycle [3]. This is
likely to explain its antiproliferative properties.
Ribonucleotide reductases are complex enzymes which cat-
alyze the reduction of ribonucleotides into the corresponding
deoxyribonucleotides. Mammalian cells, in common with oth-
er eukaryotes, DNA viruses of the Herpesvirus group and
some bacteria, notably Escherichia coli, have an iron-contain-
ing enzyme which consists of two non-identical homodimeric
subunits, R1 and R2 [4]. Each protein represents an important
target for new antiproliferative drugs [5]. Protein R1 contains
the substrate binding sites and can be irreversibly inactivated
by certain nucleotide analogs, in particular those having a
modi¢cation at the 2P position of the ribose moiety [5^8].
For example, gemcitabine, the 2P-di£uoro-2P-deoxycytidine
analog, proved to be an excellent ribonucleotide reductase
inhibitor and is now used in clinics [7].
Another strategy of inhibition relies on the fact that enzyme
activity depends on the presence of a tyrosyl radical on a
speci¢c residue of the small R2 protein [9]. Tyrosyl radical
scavenging by hydroxyurea [10] or 4-hydroxyanisole [11],
both used in clinics as anticancer agents, results in enzyme
inactivation and inhibition of DNA synthesis. This strategy
was recently revisited in the context of the research for new
drugs against the human immunode¢ciency virus (HIV), since
a combination of hydroxyurea with 3P-azido-3P-deoxythymi-
dine (AZT) or 2P,3P-dideoxyinosine (ddI) proved to have syn-
ergistic antiviral e¡ects [12^14]. In view of the secondary ef-
fects of hydroxyurea and the development of cell resistance,
due to the requirement for rather large doses of the drug,
there is a need for new, more e⁄cient inhibitors of ribonucleo-
tide reductase. Resveratrol may be a good candidate.
2. Materials and methods
2.1. Materials
Hydroxyurea and resveratrol were from Sigma; p-propoxyphenol
was from Aldrich.
Recombinant mouse R2 protein was prepared as previously de-
scribed [9] from an E. coli strain, BL21(DE3)-pETM2, containing
the mouse R2 gene, kindly provided by Professor Thelander (Univer-
sity of Umeaî, Sweden). After puri¢cation, the mouse R2 protein was
obtained in the apoprotein form. The radical site was then generated
after the anion exchange chromatography step by addition of ferrous
iron/ascorbate (molar ratio 1:2) anaerobically followed by addition of
oxygen [9]. The protein solution was transferred to ice and the excess
iron/ascorbate complex was immediately removed by gel ¢ltration on
a Sephadex G25 column. The reconstituted protein was kept in 50
mM Tris pH 7.6, 10% glycerol, frozen in liquid nitrogen and stored at
370‡C until used. Its concentration was determined with the Bradford
colorimetric assay [15] or from the absorption at 280 nm
(O280ÿ310 = 62 000 M31 cm31) [9].
2.2. Assay for tyrosyl radical scavenging ^ EPR spectroscopy
First derivative EPR spectra were recorded at 100 K on a Bruker
ESP300E spectrometer. Protein R2 was dissolved in 150 Wl of 0.1 M
Tris-HCl bu¡er pH 7.5 in order to have a ¢nal protein-bound tyrosyl
radical concentration of 10 WM. The solution was transferred to an
electron paramagnetic resonance (EPR) tube and a control spectrum
was recorded. After addition of a small volume of the radical scav-
enger solution, incubation was carried out aerobically in the EPR tube
at 37‡C and was stopped after 5 min by freezing the sample at liquid
N2 temperature. The relative amplitude of the characteristic tyrosyl
radical g = 2.00 doublet signal (normalized to 100% for the control)
was used to measure the inactivation of R2 at various concentrations
of the radical scavengers. Half-maximal inhibition values were used to
compare the e⁄ciency of the inhibitors. Recording conditions: micro-
wave power 10 mW; modulation amplitude 3.12 G.
2.3. Cell lines
L1210-R2 murine lymphoblastic leukemia cells, in which expression
of protein R2 has been ampli¢ed 15^20 times with regard to the
parental L1210 cell line [16], was used for ribonucleotide reductase
assays. K-562 human myelogenous leukemia cells and P-815 murine
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mastocytoma cells were used for assaying [3H]thymidine incorpora-
tion into DNA. These cell lines were cultured in RPMI 1640 medium
supplemented with antibiotics, 5% heat-inactivated fetal calf serum
(Gibco BRL Sarl, Cergy-Pontoise, France), and 25 mM HEPES pH
7.4.
2.4. CDP reductase assay
The L1210-R2-overexpressing cell line [16] was cultured in RPMI
1640 medium supplemented with antibiotics and 5% heat-inactivated
fetal calf serum. Cells grown in exponential phase were harvested,
washed once in phosphate-bu¡ered saline and resuspended in 100
mM HEPES pH 7.6, 15 mM magnesium acetate and 10 mM dithio-
threitol (DTT), at a concentration of 108 cells/500 Wl. Preparation of
cytosolic extracts and assay of ribonucleotide reductase were per-
formed essentially as described in [17], except that CDP concentration
was reduced to 80 WM. Inhibitors were added with the CDP substrate,
when required.
2.5. Determination of [3H]thymidine incorporation
K-562 human erythroleukemia cells and P-815 murine mastocytoma
cells were seeded in 96-well microculture plates (1U105 cells/well) in
100 Wl culture medium. Inhibitors were added in 100 Wl and the cells
were labelled with 37 kBq of [3H]thymidine (speci¢c activity 37 GBq/
mmol; Amersham, France) for 24 h at 37‡C. DNA was then har-
vested on glass ¢ber ¢lters and radioactivity determined by scintilla-
tion counting [17].
3. Results
3.1. Reaction of the tyrosyl radical in protein R2 with
resveratrol
The tyrosyl radical of pure recombinant protein R2 from
mouse exhibits an EPR doublet at 100 K at g = 2.0047 and
can thus be monitored during reaction with increasing con-
centrations of radical scavengers [11]. We found that the
catalytically essential radical (10 WM) was totally destroyed
in the presence of a stoichiometric amount of resveratrol after
5 min incubation at 37‡C (Fig. 1). Resveratrol was thus much
more active than hydroxyurea since 10 WM hydroxyurea had
almost no detectable e¡ect on the tyrosyl radical after 5 min
reaction (Fig. 1). Much higher concentrations or much longer
reaction times were required for full destruction of the tyrosyl
radical, as expected.
3.2. Inhibition of ribonucleotide reductase activity by
resveratrol
The ability of resveratrol to destroy the tyrosyl radical was
correlated with its strong dose-dependent inhibitory e¡ects on
enzyme activity, as assayed in soluble extracts of murine leu-
kemia cells containing high protein R2 expression and high
cytidine diphosphate reductase activity suitable for sensitive
and reproducible assays (Fig. 2). The IC50 value (100 WM) was
much smaller than that of hydroxyurea (1 mM). The latter
value was in the concentration range previously reported [18].
We also compared it to that of p-propoxyphenol, which was
recently claimed to be one of the most potent phenol inhib-
itors of ribonucleotide reductase [11]. The latter was found to
be signi¢cantly less active with a IC50 value of 300 WM, under
comparable conditions (Fig. 2). We thus expect an IC50 value
much below 100 WM in assays where R2 is more limiting, in
normal cells.
3.3. Inhibition of DNA synthesis by resveratrol
The antiproliferative properties of resveratrol and its inhib-
itory e¡ects on DNA synthesis were evaluated from the
[3H]thymidine incorporation into DNA assay. For these ex-
periments, we used both murine mastocytoma P-815 cells and
human myelogenous leukemia K-562 cells and again com-
pared resveratrol to hydroxyurea. Both cell lines gave com-
parable results with resveratrol being a much better inhibitor
of DNA synthesis with a IC50 value of 8^10 WM compared to
a IC50 value of 250 WM for hydroxyurea (Fig. 3). The IC50
values are signi¢cantly lower than those obtained in the CDP
reductase assay described above. This re£ects that the cells
used here are not overexpressing R2.
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Scheme 1.
Fig. 1. Inactivation of the R2 protein of mouse ribonucleotide re-
ductase by resveratrol and hydroxyurea. 10 WM of mouse protein
R2 tyrosyl radical was incubated with increased concentrations of
resveratrol (b) and hydroxyurea (a) at 37‡C for 5 min. The sample
was then frozen and assayed for its radical content by EPR spec-
troscopy at 100 K.
Fig. 2. Inhibition of mouse ribonucleotide reductase activity by
resveratrol (b), hydroxyurea (8) and p-propoxyphenol (a). 100%
activity corresponded to 100 pmol/min/mg in the experiment with
resveratrol and p-propoxyphenol and to 22 pmol/min/mg in the
experiment with hydroxyurea.
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4. Discussion
There is still a great interest in the development of inhib-
itors of ribonucleotide reductase as anticancer, antibacterial
and antiviral drugs, including for therapeutic strategies
against HIV [12^14,19]. The recent observation that resvera-
trol, a common constituent of the human diet, had cancer
chemopreventive activity [2] and the well-established fact
that ribonucleotide reductase is highly sensitive to phenol de-
rivatives led us to investigate whether resveratrol was a good
inhibitor of mammalian ribonucleotide reductase.
Our results show for the ¢rst time that indeed, at least in
vitro, resveratrol is a remarkable inhibitor of ribonucleotide
reductase. It is much more e¡ective than hydroxyurea, hy-
droxyanisole, the only ribonucleotide reductase tyrosyl radical
scavengers used in clinics, and the potent p-propoxyphenol
[11]. The most active radical scavenger described up to now
acting on ribonucleotide reductase is 5-amino-1-formyl isoqui-
noline thiosemicarbazone [20,21]. However, thiosemicarba-
zones have no application as drugs, because of their very
strong toxicity. We suggest that resveratrol should thus be
considered as an alternative to the more toxic hydroxyurea,
for example in studies of bitherapeutic approaches against
HIV.
Furthermore, our results provide new insights into the ben-
e¢cial biological activities of resveratrol. Resveratrol has in
the recent past been a subject of intense research mainly be-
cause it may be one of the key components in red wine re-
sponsible for the prevention of heart disease [1]. Inhibition of
cyclooxygenase might partly explain this e¡ect [2]. Now we
con¢rm the strong antiproliferative properties of resveratrol
and show that they are likely to be due to its ability to e⁄-
ciently scavenge the essential tyrosyl radical of the small pro-
tein of ribonucleotide reductase and, consequently, to inhibit
deoxyribonucleotide synthesis. Our data thus strongly support
the suggestion that, in addition to its cardiovascular bene¢cial
e¡ects, resveratrol merits further investigation as a cancer
chemopreventive agent in humans.
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Fig. 3. Inhibition of DNA synthesis by resveratrol and hydroxyurea.
K-562 (rounds) and P-815 (squares) tumor cells were incubated with
resveratrol (closed symbols) or hydroxyurea (open symbols) and
[3H]thymidine at 37‡C for 24 h. DNA was then harvested on a glass
¢lter and radioactivity determined by scintillation counting.
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